D-type cyclins are components of the cell-cycle engine that link cell signaling pathways and passage throughout G1 phase. We previously described the effects of overexpression cyclin D1, D2 or D3 in mouse epidermis and tumor development. We now asked whether cyclin D2 and/or cyclin D3 play a relevant role in ras-dependent tumorigenesis. Here, we described the effect of cyclin D3 and cyclin D2 overexpression in mouse skin tumor development. Notably, overexpression of cyclin D3 results in reduced tumor development and malignant progression to squamous cell carcinomas (SCC). Biochemical analysis of keratinocytes shows that overexpression of cyclin D3 results in strong reduction of cyclin D2 and its associated kinase activity. Furthermore, we found that reinstatement of cyclin D2 level in the cyclin D3/cyclin D2 bigenic mice results in a complete reversion of the inhibitory action of cyclin D3. Supporting these results, ablation of cyclin D2 results in reduced tumorigenesis and malignant progression. On the other hand, overexpression of cyclin D2 results in an increased number of papillomas and malignant progression. We conclude that cyclin D3 and cyclin D2 play opposite roles in mouse skin tumor development and that the suppressive activity of cyclin D3 is associated with cyclin D2 downregulation.
Introduction
The mammalian cell cycle is a sequential and ordered process that requires formation and activation of cyclindependent kinase complexes (CDKs). D-type cyclins are a family of key cell-cycle regulators, as they are the regulatory subunits of the CDK4 and CDK6, which phosphorylate pRb family of proteins that are critical substrates for cell-cycle progression (Matsushine et al., 1994; Meyerson and Harlow, 1994; Sherr and Roberts, 1999; Farkas et al., 2002; Leng et al., 2002) . Initially, several reports assigned redundant roles to the three members of D-type cyclins, but in the last few years, it has become evident that each member is differentially expressed in various tissues playing specific roles (Sherr, 1995; Ciemerych et al., 2002) .
The cyclin D1 gene is rearranged or amplified in breast carcinomas, squamous cell carcinomas of head and neck and several other cancers (Dickson et al., 1995; Cheung et al., 2001; Fujii et al., 2001) . Abnormalities in the cyclin D2 gene have also been demonstrated, especially in testicular tumors (Sicinski et al., 1996; Houldsworth et al., 1997) , as well as in a wide range of B-cell malignancies (Delmer et al., 1995) . Cyclin D3 was also found overexpressed in several human cancers (Ito et al., 2001; Wong et al., 2001; Hedberg et al., 2002; Pruneri et al., 2005) such as malignancies of the thymus (Filipits et al., 2002) . Consistent with these results Sicinska et al. (2003) established that cyclin D3-deficient mice displayed specific defects in the development of T lymphocytes. In addition to their growth-promoting functions, it was suggested that cyclin D3 plays a unique, nonredundant tissue-specific role such as in muscle differentiation (Kiess et al., 1995; Mariappan and Parnaik, 2005) . Cyclin D3 was also immunolocalized in quiescent cells during advanced stages of differentiation such as in the surface epithelia of the stomach, intestine, gallbladder and ureter (Bartkova et al., 1998) .
In the last few years, we and others have used the mouse skin model to study the role of D-type cyclins in normal and neoplastic proliferation (Zhang et al., 1997; Rodriguez-Puebla et al., 1998a Miliani de Marval et al., 2004) . These studies showed that cyclin D1 and D2 are overexpressed in mouse skin papillomas and squamous cell carcinomas (SCC), whereas cyclin D3 protein levels remain constant in normal epidermis and skin tumors (Rodriguez-Puebla et al., 1998b) .
In this paper, we have studied the role of cyclin D2 and cyclin D3 in skin tumorigenesis. Surprisingly, overexpression of cyclin D3 in mouse epidermis results in decreased number of skin tumors, whereas overexpression of cyclin D2 increased the number of papillomas compared to wild-type mice. Biochemical analysis show that forced expression of cyclin D3 results in a significant reduction of cyclin D2 protein levels correlating well with the reduced number of tumors observed in K5-cyclin D3 mice. We found that reinstatement of cyclin D2 levels in the K5-cyclin D3/ cyclin D2 bigenic mice overturned the reduced number of tumors, suggesting that the decreased cyclin D2 protein level is essential for the inhibitory activity observed in K5-cyclin D3 mice. Supporting this observation, ablation of cyclin D2 results in reduced number of papillomas and SCC. Thus, whereas overexpression of the three D-type cyclins produces similar epidermal phenotype, each D-type cyclin appears to play a unique role in skin carcinogenesis (RodriguezPuebla et al., 1999 (RodriguezPuebla et al., , 2000 . These observations and our previous studies suggest that cyclin D1 and cyclin D2 play a preponderant role in ras-induced tumor development, whereas deregulation of cyclin D3's ability to control cyclin D2 levels plays a central role in tumor resistance.
Results

Molecular analysis of keratinocytes overexpressing cyclin D3
The expression of murine cyclin D3 was targeted to stratified epithelial by the bovine keratin 5 gene as previously described (Ramirez et al., 1994; RodriguezPuebla et al., 2000) . As expected, cyclin D3 protein levels increased 30-fold when compared with normal sibling mice (Figure 1a, lanes 1 and 3) . In addition, we determined the status of the other D-type cyclins and found that cyclin D2 protein levels decreased 2-and 2.5-fold in epidermis and primary keratinocyte from K5-D3 mice ( Figure 1a , lanes 1 and 3 and Figure 1b ). Consistent with the cyclin D2 protein decline, cyclin D3 overexpression resulted in threefold reduction of cyclin D2 messenger levels ( Figure 1c ).
Protein lysates from epidermis of transgenic mice overexpressing cyclin D2 (K5-D2) showed that the cyclin D3 status was not affected by forced expression of cyclin D2 (Figure 1a, lanes 1 and 2) . In addition, Western blot analysis of keratinocyte from both K5-D2 and K5-D3 mice did not show changes in the cyclin D1 level (Figure 1a and b) . Collectively, all of these observations suggest that a negative feedback loop exists in mouse epidermis in which cyclin D3 normally represses the expression of cyclin D2, but not cyclin D1.
Cyclin D3-overexpressing mice exhibit reduced skin tumor development According to the current model of cell proliferation, aberrant levels of a positive regulator of cell cycle provides a growth advantage that can result in increased tumor development. Thus, we performed a two-stage chemical carcinogenesis protocol on the skin of K5-D3 mice. Tumor latency and incidence were similar in K5-D3 and wild-type mice, which began to develop papillomas at 7 weeks of promotion, and by 20 weeks, 80% of the mice had tumors (Figure 2b ). Although, a mild difference in the incidence of K5-D3 and wild-type mice was observed between weeks 7-11, both group reaches 95% of incidence when the experiment was ended (Figure 2b) . Surprisingly, K5-D3 mice averaged a significantly lower number of tumors per mice (2.5 papillomas/mouse) compared with wild-type siblings (four papillomas/mouse) (Po0.05) (Figure 2a) .
We previously observed that cyclin D2 and cyclin D1 are aberrantly expressed in mouse skin papillomas (Rodriguez-Puebla et al., 1998a) , suggesting that these cyclins play an important role in tumor development. Thus, we asked whether the reduction of cyclin D2 levels is in part responsible for the diminished tumorigenesis observed in K5-D3 mice. Therefore, we interbred transgenic mice to generate the K5-D3/K5-D2 bigenic mice. Analysis of protein lysates from epidermis of bigenic mice confirms that transgenic expression of cyclin D2 compensates for the reduction of endogenous cyclin D2 observed in K5-D3 ( Figure 1a , lane 4). We next challenged the double transgenic and K5-D2 mice to the two-stage carcinogenesis protocol. Transgenic expression of cyclin D2 resulted in an increased number of tumors (five tumors/mice) compared with wild-type mice (3.8 tumors/mice) (Po0.05). More importantly, restoration of cyclin D2 levels in the bigenic mice resulted in increased numbers of papillomas as observed in K5-D2 mice ( Figure 2a ). We conclude that cyclin D2 expression abrogates the tumor suppressive effect of cyclin D3, highlighting the importance of cyclin D2 in skin tumorigenesis.
Biochemical analysis of D-type cyclin levels in papillomas demonstrated that cyclin D2 was also downregulated in tumors from K5-D3 mice ( Figure 2d , lanes 1 and 3). Interestingly, the increased cyclin D2 protein levels in papillomas from K5-D3/K5-D2 mice (twofold) were lower than that observed in K5-D2 papillomas (10-fold) ( Figure 2d , lanes 1, 2 and 4). Because a transcriptional mechanism does not likely Role of cyclin D2 and D3 in tumor development P Rojas et al operate on an exogenous promoter in transgenic mice, a post-transcriptional mechanism may be responsible for the reduced level of cyclin D2 in mice overexpressing cyclin D3. In this case, the putative post-transcriptional mechanism would result in a reduction of the endogenous and transgenically expressed cyclin D2 as observed in K5-D3/K5-D2 bigenic mice.
Cyclin D2 overexpression also results in increased malignant progression to SCC. Figure 2c shows that 60% of the papillomas developed by both K5-D2 and K5-D2/K5-D3 bigenic mice progress to SCC at 30 weeks of tumor promotion, whereas only 40% of K5-D3 and 30% of wild-type mice progress to SCCs (Po0.05) (Figure 2c ). In addition, SCC latency was reduced in K5-D2 mice, where the first SCC appeared at 14 weeks of promotion, whereas a delay of 5-10 weeks was observed in the other genotypes (Figure 2c) . Also, an increased number of SCC per mouse (SCC multiplicity) was observed in K5-D2 (1.4 SCC/mouse) compared to wild-type mice (0.45 SCC/mouse) ( Figure 3A) .
We studied the histopathological aspect of SCCs at 30 weeks of promotion taking into account the dysplastic and anaplastic changes that included disturbed cell polarity, differentiation, abnormal mitosis, nuclear hyperchromatism and nuclear/cytoplasmic ration. Strikingly, 67% of the SCCs from K5-D2 mice presented marked atypia with areas of microinvasion and were classified as poorly differentiated SCCs ( Figure 3B ). In contrast, only 17% of SCCs from wild-type mice showed similar histopathological changes, whereas 83% were classified as moderate and well differentiated. In addition, SCCs from K5-D2/K5-D3 bigenic mice showed the same pattern of atypia observed in K5-D2 SCCs (data not shown).
We conclude that cyclin D2 overexpression enhances tumor development and malignant progression under conditions where ras is constitutively activate (ras mutation induced by 7,12-dimethylbenz[2]nthracene (DMBA) treatment). In sharp contrast, cyclin D3 overexpression results in decreased levels of cyclin D2, which in turn leads to a significantly lower number of papillomas.
Cyclin D2 ablation reduces skin tumor development Our results show that expression of cyclin D2 enhances tumor development in mouse skin. Whereas a positive role of cyclin D1 was clearly established in mouse skin tumors (Robles et al., 1998) , the question remained whether cyclin D2 is a mediator of keratinocyte transformation by oncogenic ras or is induced as a nonessential consequence of the proliferative response generated by ras transformation. To address these possibilities, we studied skin tumor development in cyclin D2-null mice. At 15 weeks of promotion, 100% of wild-type mice had tumors, whereas only 45% of the cyclin D2-null mice developed tumors. By the end of the Role of cyclin D2 and D3 in tumor development P Rojas et al observation period, 60% of the cyclin D2-null mice showed tumors (Figure 4a) . Moreover, cyclin D2-null mice average a significantly lower number of tumors per mice (4.8 papillomas/mouse) compared to wild-type sibling (9.5 papillomas/mouse) (Po0.05) (Figure 4a) .
Analysis of SCC latency showed that malignant progression was delayed 5 weeks in cyclin D2-null mice compared to wild-type sibling. In addition, the SCC incidence reached 45% in wild-type mice and 30% in cyclin D2-null mice at 38 weeks of promotion (Figure 4b ).
Cyclin D3 overexpression decreases cyclin D2/CDKs complex formation and its kinase activity We analyzed the CDKs complex formation in hyperproliferative epidermis from K5-D3 and wild-type siblings (16 h after tetradecanoyl phorbol acetate (TPA) application). In this model, one topical application of TPA on the mice's back induces a synchronized wave of keratinocyte proliferation that accelerates entry of K5-D3 keratinocytes in S phase (Supplementary material, Figure S1 ). Epidermis lysates from K5-D3 and wild-type mice were immunoprecipitated with antibodies against cyclin D1, D2 and D3, followed by Western blot analysis to determine association with CDK4 and CDK6. We found increased cyclin D3/CDK4 as well as cyclin D3/CDK6 complex formation in K5-D3 epidermis; although in our experimental conditions the later complex was hardly detected (Figure 5a, lanes 8 and 9) . As anticipated, downregulation of cyclin D2 in K5-D3 epidermis resulted in reduced cyclin D2/CDK4 complex formation compared to wild-type mice (Figure 5a , lanes 4 and 5). Analysis of CDK4/cyclin D1 showed that this complex was not affected by cyclin D3 overexpression and the consequent reduction of cyclin D2 (Figure 5a , lanes 1 and 2). It is worth mentioning that CDK6/cyclin D1 and CDK6/cyclin D2 complexes were undetectable in our experimental setting. We next asked whether changes in the level of CDK complexes results in changes in the cyclin Ds-associated kinase activities. K5-D3 mice showed fivefold increase of the cyclin D3-associated kinase activity (Figure 5b , lane 7) and, consistent with the reduced level of cyclin D2, we observed a 50% decrease of cyclin D2-associated kinase activity (Figure 5b, lane 5) . Unexpectedly, a sevenfold increase in the cyclin D1-associated kinase activity was observed in K5-D3 mice (Figure 5b, lane 2) , which is not due to changes in complex formation (Figure 5a , lanes 1 and 2). Thus, we hypothesized that mechanisms other than the simple CDK/cyclin complex formation are involved in the overactivation of cyclin D1-associated kinase activity.
In order to establish whether the elevated cyclin D3-associated kinase activity was derived from CDK4 and/ or CDK6 subunits, we also determined their in vitro kinase activities. Figure 5c shows that overexpression of cyclin D3 results in a fourfold increase in both CDK4 and CDK6 kinase activities (Figure 5c , lanes 1, 2, 4 and 5).
Discussion
In addition to its growth-promoting function, cyclin D3 expression has been associated with terminal differentiation in muscle cells (Kiess et al., 1995; Skapek et al., 1995; Mariappan and Parnaik, 2005) . Bartkova et al. (1998) have shown that cyclin D3 expression is associated with the maintenance of terminal differentiation in epithelium. Therefore, an unresolved question is whether cyclin D3 promotes cell proliferation and/or differentiation in diverse tissues.
Surprisingly, overexpression of cyclin D3 results in an inhibitory function in mouse skin tumor development. On the other hand, overexpression of cyclin D2 results in elevated numbers of tumors and increased malignant progression to SCC. Thus, it is evident that deregulated expression of each member of the D-type cyclin family affects papilloma development in a different way. Role of cyclin D2 and D3 in tumor development P Rojas et al
Our biochemical analysis revealed that overexpression of cyclin D3 results in a strong reduction of cyclin D2 level in mouse epidermis, primary keratinocyte and skin tumors. Notably, restitution of cyclin D2 levels, in the bigenic mice K5-D3/K5-D2, results in increased numbers of papillomas as observed in K5-D2 mice. We interpret this result as an indication that a mild elevation in the protein level of cyclin D2 is enough to overpass the tumor suppression effect of cyclin D3. Macroscopic and histological analysis of papillomas from K5-D3 and wild-type mice indicate no changes in the size of the tumors and/or the degree of differentiation (data nonshown). Consistent with this data, we did not observe significant differences in the levels of keratinocyte proliferation and/or apoptosis when K5-D3 tumors were compared with wild type (data not shown). These data indicate that reduced level of cyclin D2 affects the initiation stage (clonal expansion of Ha-ras-mutated cells) but not the promotion stage. In addition, these observations strongly support the notion that cyclin D2 induces tumor development and the tumor suppressive effect of cyclin D3 is associated with the reduced level of cyclin D2.
It is important to note that overexpression of cyclin D2 also promotes malignant transformation to SCC and it is not affected by reduction of the endogenous cyclin D2 in K5-D3/K5-D2 bigenic mice. Also, the reduction of cyclin D2 levels in K5-D3 epidermis does not decrease the rate of malignant transformation that is similar to the percentage observed in wild-type mice. These findings support the notion that the level of cyclin D2 strongly affects papilloma development, but malignant transformation to SCC required a threshold level of cyclin D2. Supporting the oncogenic activity of cyclin D2, depletion of this cyclin result in decrease number of papillomas and strong reduction of malignant progression to SCCs. Thus, using a model of ras-mediated tumorigenesis of mouse skin in a cyclin D2-deficient background, we have provided genetic evidence of the role of cyclin D2 as a downstream mediator of oncogenic ras.
Analysis of epidermis from K5-D3 mice shows not only reduction of cyclin D2 protein levels but also a reduction of cyclin D2 mRNA. These data suggest that a transcriptional mechanism is responsible for the negative feedback loop that regulates cyclin D2 levels. However, a more detailed analysis of skin tumors showed that the level of cyclin D2 was elevated 10-fold in papillomas from K5-D2 mice, whereas a mere two times increase was observed in papillomas from K5-D3/ K5-D2 mice (Figure 2d ). These results suggest that overexpression of cyclin D3 in tumors from the bigenic mice results in reduction not only of the endogenous but also the transgenically expressed cyclin D2. In this scenario, the level of the transgenically expressed cyclin D2 is probably not regulated at the transcriptional level, as an exogenous promoter was used to drive its expression, and it is unlikely that the mechanism involved in the reduction of cyclin D2 mRNA acts through an external promoter. Hence, a post-transcriptional mechanism is likely involved in the negative feedback loop.
In vivo kinetic analysis demonstrated that overexpression of cyclin D3, and the consequent reduction of cyclin D2 levels, does not decrease the rate of keratinocyte proliferation. In fact, the entry into S phase is Role of cyclin D2 and D3 in tumor development P Rojas et al accelerated in K5-D3 keratinocytes compared to wildtype mice (Supplementary material, Figure S1 ).
Our biochemical analysis established that the decreased cyclin D2/CDK complexes and cyclin D2-associated kinase activities are compensated by an increase in cyclin D3 and cyclin D1 kinase activities. Whereas the increased cyclin D3 kinase activity correlated well with the elevated cyclin D3/CDK complexes, increased cyclin D1-associated kinase activity is not due to increased complex formation. It is plausible that the elevated cyclin D3/CDK complexes bind to p27 and/or p21 releasing cyclin D1/CDK of these inhibitors and consequently increasing the kinase activities without increasing the level of cyclin D1/CDK complexes.
Altogether, we interpreted our results as an indication that cyclin D2 appears to play an important role in skin tumorigenesis, although the reduced level is well tolerated by normal keratinocytes. Indeed, the generation of cyclin D1, cyclin D2 and cyclin D3 knockout mice confirmed that keratinocytes stand very well the ablation of any of these genes (Sicinski et al., 1996 (Sicinski et al., , 1995 (Sicinski et al., , 2003 . In addition, ablation of two members of the D-type cyclin family results in normal development of the 'single-cyclin' mice until late gestation (Ciemerych et al., 2002) , without defects in skin development (Sicinski, personal communication) .
It is worth mentioning that cyclin D1 protein is more stable in cell lines derived from SCC compared to Figure 5 CDKs complex formation and kinase activities in epidermis from transgenic mice. At 16 h after TPA treatment, fresh protein lysates from epidermis of K5-D3 and wild-type mice were immunoprecipitated with antibodies against cyclin D1 (D1), cyclin D2 (D2), cyclin D3 (D3), CDK4, CDK6 or normal rabbit serum (NR). (a) D-type cyclins' immunoprecipitates were immunoblotted with antibodies against CDK4, CDK6 and the corresponding D-type cyclin. Protein lysates from CDK4-null mice (CDK4 KO) was used as control to determine the specificity of the CDK antibodies. (b and c), D-type cyclins, CDK4 and CDK6 kinase activities were determined in the immunoprecipitates using a pRb peptide as substrate. Kinase activities were quantified with a densitometer.
Role of cyclin D2 and D3 in tumor development P Rojas et al keratinocytes and papillomas cell lines. On the other hand, cyclin D3 stability is increased in non-malignant cell lines (Supplementary material, Figure S2 ).
Ultimately, these results demonstrate that inhibition or activation of D-type cyclins will affect the outcome of tumors in different ways. Mouse skin tumor experiments demonstrate that whereas cyclin D2 overexpression increase tumor development, cyclin D1 does not affect tumorigenesis (Rodriguez-Puebla et al., 1999) , and cyclin D3 results in reduction of the number of tumors associated to decrease the cyclin D2 level. Therefore, it is necessary to determine whether positive and negative feedback loops exist in different tissues regulating the D-type cyclin levels. In the final analysis, these feedback loops could represent possible targets for future cancer therapies.
Materials and methods
Experimental animals FVB/N-K5-Ccnd2 (K5-D2) and FVB/N-K5-Ccnd3 (K5-D3) transgenic mice generation was previously described (RodriguezPuebla et al., 2000) . Bigenic mice K5-D2/K5-D3 were obtained by interbreeding K5-D2 and K5-D3 transgenic mice. Cyclin D2-null mice were provided by Dr Piotr Sicinski (Sicinski et al., 1996) .
Two-stage carcinogenesis protocol
Initiation was performed by a single topical application of DMBA (3.9 mM in 50 ml of acetone) on the dorsal skin of newborn mice. At 3 weeks after DMBA initiation, TPA (32.4 mM in 200 ml of acetone) was applied twice a week on each mouse's dorsal skin. Mouse skin and tumors were grounded in homogenization buffer (60 mM Tris-HCl, pH 8.6, 5 mM ethylenediaminetetraacetate (EDTA), 5 mM ethylene glycolbis(2-aminoethyl ether)-N,N,N 0 ,N 0 -tetraacetic acid (EGTA), 300 mM sucrose, anti-protease and anti-phosphatase cocktails). The homogenates were sonicated and centrifuged at 10 000 g for 10 min. The supernatants were collected and used directly for Western blot analysis.
Western blot analysis
Skin proteins were obtained as previously described (RodriguezPuebla et al., 1998a) . Protein lysates (25-50 mg) were electrophoresed and transferred onto nitrocellulose membranes. Western blot analysis was performed with the following antibodies: cyclin D1 (C-20), cyclin D2 (M-20), cyclin D3 (C-16), CDK4 (C-22), b-actin (I-19) (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), and CDK6 Ab-2 (K6.90) (Labvision-NeoMarkers Co., Fremont, CA, USA).
Immunoprecipitation assay
The skin of TPA-treated mice (16 h after TPA treatment) was scraped off with a razor blade, and homogenized in lysis buffer (25 mM HEPES (pH 7), 5 mM EDTA, 50 mM NaCl, 50 mM NaFl, 10% glycerol, 1% Triton X-100, antiprotease and anti-phosphatase cocktails). The epidermal homogenate was centrifuged at 10 000 g and supernatant was used directly for immunoprecipitation assay with protein A-agarose beads and specific antibodies. Immunoprecipitates were electrophoresed and transferred onto nitrocellulose membranes.
Kinase activity assay Protein lysates were obtained as described above, and centrifuged at 10 000 g for 30 min at 41C. The supernatant was collected and used for a kinase assay.
Protein lysates (250 mg) were immunoprecipitated with antibodies against CDK4, CDK6, cyclin D1, cyclin D2 or cyclin D3. Antibody-precoated beads were incubated with the lysates for 1 h at 41C, washed twice with Tween-20 buffer and kinase buffer and further incubated with pRb substrate and [g-32 P]ATP (Rodriguez-Puebla et al., 2000) . Sodium dodecyl sulfate (SDS) sample buffer was added and electrophoresed through acrylamide gels.
Statistical analysis
Statistical analysis was performed using GraphPad Software (GraphPad Software, San Diego, CA, USA).
